Navigation Links
Heart Devices Not Tested Enough in Women: Study
Date:3/1/2011

By Steven Reinberg
HealthDay Reporter

TUESDAY, March 1 (HealthDay News) -- On top of criticism that the U.S. Food and Drug Administration approves medical devices with too little oversight comes another troubling finding: Many heart-related devices win FDA approval without being adequately tested on women, despite an agency directive to do so.

This means that heart valves, pacemakers, defibrillators and stents get implanted in women without evidence that they benefit this population, researchers from the University of California, San Francisco say.

"We do not know if a lot of medical devices currently on the market are as safe and effective in women as they are in men," said lead researcher Dr. Rita F. Redberg, a professor of medicine and director of Women's Cardiovascular Services at the university and a member of the FDA Circulatory System Devices Panel.

"The FDA needs to turn away device applications that don't have a gender-bias statement," said Redberg, senior author of the study, published online March 1 in Circulation: Cardiovascular Quality and Outcomes.

Differences in size and bleeding tendencies can affect the way these devices operate in men and women, and side effects can also vary by gender, Redberg said.

Recognizing those distinctions, in 1994 the FDA mandated that manufacturers of new medical devices provide statements that the devices were tested in men and women in the same proportion as men and women experiencing the condition that the device would treat, Redberg said.

The data is also supposed to include any safety or effectiveness problems seen in women using the device.

Redberg's team looked at 123 studies submitted with premarket approval applications for 78 high-risk cardiovascular devices, including heart valves and implanted defibrillators. All the devices were approved by the FDA between 2000 and 2007.

During that period, a time when women's heart disease was gaining unprecedented attention, there was no increase in the proportion of women participating in studies or the number of applications with gender-bias statements, Redberg said.

FDA summaries of 28 percent of the studies made no mention of gender. Of those that did, men made up 67 percent of the study participants, the researchers found.

In addition, only 41 percent of the studies included the required gender statement. Of these, 94 percent showed results by sex, and 26 percent found sex-related differences in the safety and effectiveness, the researchers found.

Only 11 percent of the studies without gender-bias statements included any performance data related to gender difference. Studies of fewer than 50 patients were not included in the sex-based analysis, the authors noted.

Among applications the agency approved, device makers erroneously excluded women from studies, the researchers found. Some manufacturers understated the number of women with a specific heart condition. Other times, they said their study included an equivalent number of women as earlier studies, without acknowledging that those prior studies included only a token number of women.

Since data are not available about devices that the FDA didn't approve, Redberg's team couldn't determine how many of these included gender data.

The FDA, meanwhile, says it is working to correct these shortcomings.

"The findings reported in this study are not new," said FDA spokeswoman Karen Riley. "FDA is aware of the under-representation of women in clinical trials," she added.

Recently, the FDA division that approves medical devices has come under fire from the medical community for approving devices too fast without proper data, while device manufacturers complain it doesn't approve devices fast enough and over-complicates the process.

The agency's own 2009 study found that women, children and minorities were underrepresented in premarket cardiovascular clinical trials. "Women were less often enrolled in the studies than men (33.9 percent versus 66.1 percent)," Riley said.

The agency will issue guidance on gender this year, Riley added. "Interim policy improvements are already under way, intended to address the need for greater consistency in sex-specific analysis and availability of sex-specific information for approved medical devices," she said.

Commenting on the study, Dr. Nieca Goldberg, director of the Women's Heart Program at NYU Langone Medical Center in New York City, said more must be done on women's behalf.

"There has to be greater oversight," Goldberg said. "We have to meet the needs and expectations of women."

A woman needs to ask her doctor about the risks and benefits of these devices, Goldberg said.

"But we can't stop women from having these procedures if they really meet the indications," she said.

Redberg, who was speaking independently of her role with the FDA, says stricter enforcement of guidelines is needed.

More information

For more information on women and heart disease, visit the American Heart Association.

SOURCES: Rita F. Redberg, M.D., M.Sc., professor, medicine, and director, Women's Cardiovascular Services, University of California, San Francisco; Karen Riley, M.P.H., spokeswoman, U.S. Food and Drug Administration; Nieca Goldberg, M.D., director, Women's Heart Program, NYU Langone Medical Center, New York City; March 1, 2011, Circulation: Cardiovascular Quality and Outcomes, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. ICU Patients at Risk for Rare Heart Rhythm Problem
2. Cook With Love This Valentines Day With Heart-Smart Recipes
3. Study finds racial gaps continue in heart disease awareness
4. Highmark Foundation Awards $120,000 to the American Heart Association
5. Womens Heart Disease Awareness Still Lacking
6. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
7. Migraine Linked to Increased Heart Attack Risk
8. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
9. Compound shows promise against intractable heart failure
10. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
11. Ex-President Clinton Undergoes Heart Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Heart Devices Not Tested Enough in Women: Study 
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... ... an inspirational interview of two ostomy patients, standing as living proof that attitude ... suffer from digestive diseases and issues that spike around the holidays. This campaign ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology: